IGM Biosciences, Inc. operates as a biotechnology firm dedicated to advancing Immunoglobulin M (IgM) antibodies. These novel therapeutic agents are being developed for a broad spectrum of conditions, including various cancers, infectious ailments, and autoimmune and inflammatory disorders. The company's most advanced experimental treatment is IGM-2323, a bispecific IgM antibody.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 31, 2025 | -$0.30 | $1.58 | Beat |
| May 13, 2025 | -$0.41 | -$0.86 | Miss |
| May 6, 2025 | -$0.45 | -$0.61 | Miss |
| Nov 8, 2024 | -$0.82 | -$1.01 | Miss |
| Aug 14, 2024 | -$0.04 | -$0.79 | Miss |
| May 8, 2024 | -$0.84 | -$0.83 | Beat |